Clinical Trial Update: Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Everolimus in combination with DHAP for relapsed or refractory Hodgkin Lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• DHAP (dexamethasone, high-dose cytarabine, cisplatin)
• Everolimus (everolimus)

Snippet

Sponsor: University of Cologne | Conditions: Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED